REGISTER NOW TO BECOME A MEMBER

You are viewing the 1st of the 2 courses UPMC Physician Resources permits you to view without registering. To have full access to our FREE courses on our website, please register or log in now.
Register

This edition of Cancer Insights features three case studies that highlights some of our most promising research and clinical trials. The first case study compares cytotoxic chemotherapy regimens and the role of anti-EGFR antibody therapy in treating patients with metastatic colorectal cancer. The second case study discusses how the measurement of tumor apoptosis could predict response to stereotacticradiosurgery. The third case study considers the therapeutic options for the management of malignant peritoneal mesothelioma and recommendations regarding standard of care.

Educational objectives:

 Upon completion of this activity, participants should be able to:

  • Describe the role of stereotactic radiosurgery (SRS) in the management of brain metastases.
  • Discuss how measurement of tumor apoptosis could predict response to SRS.
  • Discuss the clinical presentation, risk factors and diagnostic work-up of malignant peritoneal mesothelioma.
  • List the available therapeutic options for the management of malignant peritoneal mesothelioma and recommendations regarding standard of care.
  • Identify the molecular markers and targeted therapies undergoing pre-clinical and clinical investigation.
  • Review the cytotoxic chemotherapy regimens that can be used to treat patients with metastatic colorectal cancer.
  • Assess the role of biological agents in the treatment of metastatic colorectal cancer and explain the role of KRAS status in determining the potential clinical efficacy of anti-EGFR antibody therapy.

Reading Resources:

  1. Munkholm-Larsen, S., C.Q. Cao, and T.D. Yan, Malignant peritoneal mesothelioma. World J Gastrointest Surg, 2009. 1(1): p. 38-48.
  2. Gaspar L, Scott,C, Rotman,M et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
  3. Lee JJ and Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007;13:276-281.

Disclosures:

Drs Bartlett,  Choudry, Clump, Heron and Mintz, have no relevant relationships with any entities producing healthcare goods or services.
Dr. Chu has financial interests with the following any entity or entities producing health care goods or services: Roche, Genentech.

Accreditation Statement:

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.05) continuing education units (CEU) which are equivalent to 0.5 contact hours.

For your credit transcript, please access our website 4 weeks post-completion at http://ccehs.upmc.edu and follow the link to the Credit Transcript page. If you do not provide the last 5 digits of your SSN on the next page you will not be able to access a CME credit transcript. Providing your SSN is voluntary.

Release Date: 7/16/2012 | Last Modified On: 7/16/2012 | Expires: 7/16/2013

This course has been expired.